Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

NCT00633997 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome.

Conditions

Interventions

Sponsor

Novartis